


Munich Cancer Registry



- ▶ Survival
- ▶ Selection Matrix
- ▶ Homepage
- ▶ *Deutsch*

Munich Cancer Registry at Munich Cancer Center
Marchioninstr. 15
Munich, 81377
Germany

<http://www.tumorregister-muenchen.de/en>

Cancer statistics: Baseline statistics

C15-C26: GI cancer

Year of diagnosis	1998-2013
Patients	79,446
Diseases	81,944
Creation date	05/19/2015
Export date	12/30/2014
Population	4.64 m



http://www.tumorregister-muenchen.de/en/facts/base/base_C1526E.pdf

Global Statements about the statistics on the Internet –
Baseline Statistics (grey button) , **Survival** (red button)

In these analyses, the clinics and physicians of Upper Bavaria and the city and county of Landshut[#], with a total of 4.64 million inhabitants, account for the frequency of cancer diseases^{##} and the achieved long term results. Additionally, the long term survival evaluated by the Munich Cancer Registry (MCR) is compared with the results of the population-based registry in the USA (SEER), which is useful for checking the consistency of the data on an international level.

In comparing several tables, inconsistent figures may be detected. This is based on the fact that different patient cohorts are included in the base calculation, for example when proportions of multiple tumors or DCO-cases^{###} are concerned. In other cases the individual tumor diagnosis is the basis for calculation, for example with incidence.

The foot notes describe the currentness of the data. The baseline statistics and survival data are updated annually. This yearly analysis comprises the Annual Report of the MCR. The time-delayed acquisition of data and the occasionally high DCO-rates indicate optimizing reserves, among others, because of current financial and legal conditions that hinder the analyses.

Clinics and physicians have access to essentially more detailed data, with which they can check, compare and in the best case optimize their own data and results.

We would be pleased to receive corrections, critique and useful suggestions. Just send an e-mail to tumor@ibe.med.uni-muenchen.de.

Munich Cancer Registry, May 2015

- [#] Base data has been collected since 1998. An increase in new diseases is apparent, which is an effect of two extensions in the MCR catchment area (from a base population of 2.51 million to 3.96 in 2002, and to 4.52 million in 2007). Death certificates from 2014 are incorporated into these analyses.
- ^{##} Due to the high frequency and good prognosis of non-malignant skin cancer (C44), no systematic ascertainment is performed for this diagnosis. C44 is not designated as a primary, but rather as a secondary tumor.
- ^{###} DCO (death certificate only) identifies a cancer case that first becomes available to the MCR through the death certificate. A high proportion of DCO cases (≥5%) in particular cancer types indicate insufficient participation of specific cancer specializations.

ICD-10 codes (ICD-10 2015) used for specifying cancer site

Code	Description
C15	Oesophagus
C16	Stomach
C17	Small intestine
C18	Colon
C19	Rectosigmoid junction
C20	Rectum
C21	Anus and anal canal
C22	Liver and intrahepatic bile ducts
C23	Gallbladder
C24	Other and unspecified parts of biliary tract
C25	Pancreas
C26	Other and ill-defined digestive organs

INCIDENCE

Table 1

Patient cohorts by year of diagnosis including DCO cases and multiple primaries, and with proportion of deaths and active follow-up

Year of diagnosis	Cases n	DCO cases n	Prop. DCO %	Prop. mult. primaries %	Prop. deaths %	Prop. actively followed %
1998	3204	376	11.7	20.1	80.5	98.6
1999	3257	408	12.5	20.6	80.2	98.2
2000	3045	416	13.7	22.1	79.3	98.7
2001	3336	466	14.0	22.4	76.0	97.9
2002	5717	1106	19.3	22.5	78.6	98.6 #
2003	5495	878	16.0	22.8	74.3	98.5
2004	5545	790	14.2	22.8	73.4	97.9
2005	5465	735	13.4	25.0	73.4	97.6
2006	5630	603	10.7	24.9	69.1	96.4
2007	6334	713	11.3	23.6	68.4	89.3 # ##
2008	6335	692	10.9	24.8	65.7	79.4
2009	6290	657	10.4	24.4	62.8	78.0
2010	6021	633	10.5	24.4	60.3	76.8
2011	5961	604	10.1	24.5	56.2	76.0
2012	5904	611	10.3	24.0	48.9	76.9
2013	4405	578	13.1	24.3	36.2	98.5 ###
1998-2013	81944	10266	12.5	23.6	66.6	89.7

The increases of incident cases in 2002 and 2007 reflect the expansion to additional registry areas.

Since 2007 the percentage of actively followed patients sharply declined compared to the previous years. This is a consequence of ambiguous data protection rules that currently forbid cancer registries in Bavaria to obtain the essential life status informations from competent registration offices.

Please be aware that data of recent annual patient cohorts may not yet be fully processed. Therefore, the presented figures and tables are potentially related to different time periods as pointed out in the respective headlines or legends.

Table 1a

Patient cohorts by year of diagnosis and gender
including DCO cases

Year of diagnosis	All n	Males n	Females n	Prop. males %
1998	3204	1660	1544	51.8
1999	3257	1719	1538	52.8
2000	3045	1635	1410	53.7
2001	3336	1784	1552	53.5
2002	5717	3069	2648	53.7
2003	5495	2970	2525	54.0
2004	5545	3000	2545	54.1
2005	5465	2964	2501	54.2
2006	5630	3116	2514	55.3
2007	6334	3585	2749	56.6
2008	6335	3554	2781	56.1
2009	6290	3598	2692	57.2
2010	6021	3423	2598	56.9
2011	5961	3389	2572	56.9
2012	5904	3328	2576	56.4
2013	4405	2506	1899	56.9
1998-2013	81944	45300	36644	55.3

Table 2

Incidence measures by year of diagnosis and gender including DCO cases
(with respect to registry area expansion from 2.51 to 3.96 m as of 2002,
and from 3.96 to 4.64 m as of 2007, respectively)

Year of diagnosis	Males n	Females n	Males Inc. raw	Fem. Inc. raw	Males Inc. WS	Fem. Inc. WS	Males Inc. ES	Fem. Inc. ES	Males Inc. BRD-S	Fem. Inc. BRD-S
1998	1660	1544	149.8	131.3	90.0	54.8	136.1	83.1	178.4	110.0
1999	1719	1538	153.6	129.6	90.8	53.2	137.6	81.0	180.6	107.4
2000	1635	1410	143.6	117.4	84.3	47.2	127.6	72.6	164.9	96.7
2001	1784	1552	153.9	127.6	90.0	54.2	135.3	81.6	174.3	106.2
2002	3069	2648	164.7	135.2	92.3	53.6	139.2	81.7	181.0	108.3
2003	2970	2525	158.4	128.2	87.0	51.4	131.4	78.1	171.3	102.2
2004	3000	2545	159.5	128.7	85.9	52.8	129.6	79.2	168.9	102.7
2005	2964	2501	156.5	125.7	82.7	49.2	124.3	74.4	162.0	98.1
2006	3116	2514	162.7	125.1	85.4	49.8	128.0	75.1	165.8	98.3
2007	3585	2749	161.8	119.0	84.7	46.8	126.4	70.6	163.7	92.1
2008	3554	2781	159.7	119.8	81.2	46.8	121.7	70.4	157.8	91.9
2009	3598	2692	161.2	115.8	80.1	44.8	120.2	67.6	156.3	88.5
2010	3423	2598	151.9	111.0	75.2	42.0	112.7	63.5	145.7	83.9
2011	3389	2572	148.3	109.0	71.9	42.2	107.6	63.2	139.9	81.6
2012	3328	2576	145.7	109.2	71.6	43.5	107.0	64.5	137.5	83.3
2013	2506	1899	109.7	80.5	52.7	31.6	79.6	47.2	104.0	61.4
1998-2013	45300	36644	152.4	118.0	79.5	46.7	119.4	70.4	154.9	92.1

The computation of the incidence measures includes all primaries, irrespective of first or subsequent malignancy.

Table 3

Age distribution parameters by year of diagnosis (All)
(incl. DCO)

Year of diagnosis	Cases n	Mean	Std. dev.	Min.	Max.	10%	25%	Median 50%	75%	90%
1998	3204	70.3	12.7	13.2	102	53.4	61.0	71.6	79.3	86.3
1999	3257	70.6	12.6	10.8	102	54.6	62.0	71.6	79.6	86.5
2000	3045	70.6	12.5	21.7	103	54.4	61.8	71.7	79.5	86.9
2001	3336	70.1	12.7	0.6	103	53.9	61.6	70.6	79.5	86.7
2002	5717	71.1	12.3	17.7	104	55.1	62.7	72.1	80.3	87.0
2003	5495	71.1	12.1	8.4	101	55.6	63.1	71.9	80.2	86.3
2004	5545	70.7	12.3	3.1	101	54.7	62.9	71.2	80.0	85.5
2005	5465	71.3	12.3	1.0	100	55.9	63.7	71.7	80.4	86.0
2006	5630	70.8	12.2	12.3	102	54.9	63.2	71.4	80.1	85.6
2007	6334	70.8	12.4	0.3	103	54.3	63.4	71.4	80.2	86.1
2008	6335	71.2	12.4	1.1	105	55.0	63.9	71.9	80.4	86.3
2009	6290	71.2	12.3	3.7	102	54.5	63.8	72.0	80.3	86.3
2010	6021	71.3	12.4	0.8	103	54.6	63.6	72.2	80.8	86.2
2011	5961	71.4	12.5	0.7	101	54.3	63.9	72.4	80.7	86.8
2012	5904	71.0	12.6	0.0	101	54.5	63.5	72.3	79.9	86.1
2013	4405	71.2	12.5	2.7	105	54.1	63.6	72.9	79.9	86.2
1998-2013	81944	71.0	12.4	0.0	105	54.6	63.1	71.9	80.2	86.3

Table 3a

Age distribution parameters by year of diagnosis (MALES)
(incl. DCO)

Year of diagnosis	Cases n	Mean	Std. dev.	Min.	Max.	10%	25%	Median 50%	75%	90%
1998	1660	67.9	12.1	16.5	98.1	52.3	58.9	68.6	76.7	84.0
1999	1719	68.3	11.9	10.8	97.4	53.8	60.2	68.8	76.9	83.6
2000	1635	68.4	11.6	25.1	97.8	53.9	60.4	68.6	76.7	84.3
2001	1784	68.0	11.8	14.5	102	53.5	60.6	67.9	76.7	83.5
2002	3069	69.0	11.3	20.9	98.5	54.4	61.6	69.3	76.8	82.8
2003	2970	69.2	11.3	8.4	99.4	55.0	62.4	69.4	76.9	83.0
2004	3000	69.1	11.3	22.5	101	54.4	62.0	69.2	77.1	83.7
2005	2964	69.2	11.3	19.0	99.6	55.0	62.5	69.3	77.3	83.5
2006	3116	69.0	11.3	12.3	102	54.7	62.2	69.3	77.1	83.0
2007	3585	68.9	11.8	0.3	99.4	53.7	62.0	69.4	77.6	83.3
2008	3554	69.5	11.4	6.5	105	54.6	62.7	70.1	77.7	83.4
2009	3598	69.7	11.4	3.7	102	54.1	62.7	70.8	77.8	83.4
2010	3423	69.7	11.6	0.8	98.9	54.3	62.1	70.6	78.1	83.8
2011	3389	70.1	11.6	0.8	97.3	54.2	63.4	71.4	78.2	84.2
2012	3328	69.9	11.4	0.0	101	55.0	62.8	71.1	77.7	83.8
2013	2506	70.2	11.6	19.4	99.8	54.5	63.0	71.9	78.3	84.1
1998-2013	45300	69.3	11.5	0.0	105	54.3	62.0	70.0	77.4	83.5

Table 3b

Age distribution parameters by year of diagnosis (FEMALES)
(incl. DCO)

Year of diagnosis	Cases n	Mean	Std. dev.	Min.	Max.	10%	25%	Median 50%	75%	90%
1998	1544	72.8	12.8	13.2	102	54.5	64.2	74.9	83.0	87.7
1999	1538	73.3	12.9	18.8	102	55.8	64.6	75.1	82.9	88.5
2000	1410	73.2	13.0	21.7	103	55.5	64.1	75.7	82.3	88.4
2001	1552	72.4	13.3	0.6	103	54.9	63.3	74.6	81.8	88.8
2002	2648	73.7	12.8	17.7	104	56.0	65.0	76.0	82.5	89.0
2003	2525	73.3	12.6	10.9	101	56.4	64.5	75.3	82.7	88.6
2004	2545	72.6	13.1	3.1	100	55.1	64.3	74.3	82.8	88.0
2005	2501	73.8	12.9	1.0	100	57.2	65.4	75.5	83.1	89.6
2006	2514	73.0	12.9	20.4	99.2	55.0	64.9	75.0	83.1	87.4
2007	2749	73.3	12.9	17.8	103	55.2	65.7	74.7	83.2	87.7
2008	2781	73.5	13.3	1.1	102	55.4	65.4	74.7	83.7	88.3
2009	2692	73.3	13.1	15.9	102	55.2	65.5	75.0	83.3	88.2
2010	2598	73.6	13.0	14.9	103	55.4	66.4	75.3	83.4	88.2
2011	2572	73.1	13.5	0.7	101	54.4	65.0	74.6	83.5	88.7
2012	2576	72.4	13.8	1.6	101	53.8	64.7	74.3	82.7	88.4
2013	1899	72.5	13.5	2.7	105	53.4	65.1	74.4	82.5	88.4
1998-2013	36644	73.1	13.1	0.6	105	55.2	64.9	74.9	83.0	88.4

Table 4

Age distribution by 5-year age group and gender for period 1998-2013
(incl. DC0)

Age at diagnosis Years	Cases			Males			Females		
	n	%	Cum.%	n	%	Cum.%	n	%	Cum.%
0-4	18	0.0	0.0	8	0.0	0.0	10	0.0	0.0
5-9	5	0.0	0.0	4	0.0	0.0	1	0.0	0.0
10-14	9	0.0	0.0	4	0.0	0.0	5	0.0	0.0
15-19	37	0.0	0.1	10	0.0	0.1	27	0.1	0.1
20-24	55	0.1	0.2	16	0.0	0.1	39	0.1	0.2
25-29	132	0.2	0.3	60	0.1	0.2	72	0.2	0.4
30-34	275	0.3	0.6	134	0.3	0.5	141	0.4	0.8
35-39	536	0.7	1.3	301	0.7	1.2	235	0.6	1.4
40-44	1160	1.4	2.7	654	1.4	2.6	506	1.4	2.8
45-49	2318	2.8	5.5	1341	3.0	5.6	977	2.7	5.5
50-54	4009	4.9	10.4	2432	5.4	11.0	1577	4.3	9.8
55-59	6408	7.8	18.3	4143	9.1	20.1	2265	6.2	16.0
60-64	9496	11.6	29.8	6140	13.6	33.7	3356	9.2	25.1
65-69	11584	14.1	44.0	7479	16.5	50.2	4105	11.2	36.3
70-74	12917	15.8	59.7	7834	17.3	67.5	5083	13.9	50.2
75-79	12181	14.9	74.6	6622	14.6	82.1	5559	15.2	65.4
80-84	10482	12.8	87.4	4694	10.4	92.4	5788	15.8	81.2
85+	10322	12.6	100.0	3424	7.6	100.0	6898	18.8	100.0
All ages	81944	100.0		45300	100.0		36644	100.0	

Included in the statistics are 27.9% multiple primaries in males and 23.4% in females.

Table 5

Age-specific incidence, DCO rate and proportion of all cancers
for period 1998-2013

Age at diagnosis Years	Males n	Females n	Males Age- spec. incid.	Females Age- spec. incid.	Males DCO rate n=4562 %	Females DCO rate n=5566 %	Males Prop.all cancers n=158258 %	Females Prop.all cancers n=153136 %
0- 4	8	10	0.5	0.7	12.5		2.5	4.1
5- 9	4	1	0.3	0.1			2.3	0.8
10-14	4	5	0.3	0.3			2.4	2.9
15-19	10	27	0.6	1.8			2.8	9.2
20-24	16	39	0.9	2.2	18.8		2.6	7.4
25-29	57	72	2.8	3.5		1.4	5.9	6.5
30-34	134	140	5.9	6.3	1.5	2.9	8.9	6.8
35-39	297	234	11.9	9.9	2.0	3.4	13.2	6.3
40-44	651	504	24.8	20.3	2.0	1.2	20.3	8.1
45-49	1327	969	56.2	41.9	3.5	2.5	24.8	11.1
50-54	2399	1569	118.8	76.3	6.0	2.8	27.8	14.2
55-59	4085	2239	222.7	116.4	5.1	3.6	28.2	16.4
60-64	6030	3314	340.2	176.7	5.9	4.5	27.7	19.2
65-69	7333	4053	464.5	234.9	7.3	6.3	26.7	21.4
70-74	7649	5003	597.1	329.5	8.0	8.3	28.5	27.2
75-79	6480	5470	784.0	460.5	11.8	13.4	31.4	31.1
80-84	4569	5698	913.2	610.8	17.9	20.9	33.5	36.1
85+	3356	6802	984.1	761.0	31.4	39.0	33.7	39.6
All ages	44409	36149			10.3	15.4	28.1	23.6
Incidence								
Raw			149.4	116.4				
WS			78.1	46.1				
ES			117.1	69.5				
BRD-S			151.8	90.9				

The age-specific incidence characterizes the disease risk in a particular age group. The age distribution depends on the patient population frequency in each age group and reflects the tangible clinical picture of everyday patients care (see following chart).

Table 6a

Standardized incidence ratio (SIR, with 95% confidence limits),
excess absolute risk (EAR) and DCO rate of second primaries
for period 1998-2013

MALES

Diagnosis	Observed n	Expected n	SIR	LCL 95%	UCL 95%	EAR	DCO %
C00 Lip	4	1.9	2.1	0.6	5.3	0.2	
C03-C06 Oral cavity	28	12.0	2.3	1.6	3.4 #	1.9	3.6
C07-C08 Salivary gland	5	3.4	1.5	0.5	3.4	0.2	
C09-C10 Oropharynx	40	14.3	2.8	2.0	3.8 #	3.1	2.5
C12-C13 Hypopharynx	14	8.0	1.7	1.0	2.9	0.7	7.1
C15 Oesophagus	50	26.1	1.9	1.4	2.5 #	2.9	12.0
C16 Stomach	136	67.9	2.0	1.7	2.4 #	8.2	8.1
C17 Small intestine	51	7.3	6.9	5.2	9.1 #	5.3	2.0
C18 Colon	421	160.2	2.6	2.4	2.9 #	31.4	4.0
C19-C20 Rectum	192	85.6	2.2	1.9	2.6 #	12.8	2.1
C21 Anus/canal	9	3.0	3.0	1.4	5.6 #	0.7	11.1
C22 Liver	101	42.3	2.4	1.9	2.9 #	7.1	23.8
C23-C24 Bile	35	15.4	2.3	1.6	3.2 #	2.4	14.3
C25 Pancreas	124	56.1	2.2	1.8	2.6 #	8.2	23.4
C26 GI cancer	3	2.1	1.4	0.3	4.1	0.1	33.3
C32 Larynx	31	15.2	2.0	1.4	2.9 #	1.9	16.1
C33-C34 Lung	380	182.3	2.1	1.9	2.3 #	23.8	15.8
C38,C45 Mesothelioma	12	10.2	1.2	0.6	2.1	0.2	
C43 Malign. melanoma	103	58.5	1.8	1.4	2.1 #	5.4	1.0
C46,C49 Soft tissue	21	8.2	2.6	1.6	3.9 #	1.5	4.8
C48 Peritoneal	3	1.0	2.9	0.6	8.4	0.2	66.7
C50 Breast	11	4.0	2.8	1.4	4.9 #	0.8	45.5
C60 Penis	6	3.5	1.7	0.6	3.7	0.3	
C61 Prostate	702	470.0	1.5	1.4	1.6 #	27.9	9.4
C62 Testis	9	3.1	2.9	1.3	5.6 #	0.7	11.1
C64 Kidney	148	53.2	2.8	2.4	3.3 #	11.4	6.1
C65 Renal pelvis	19	6.6	2.9	1.7	4.5 #	1.5	
C66 Ureter	14	3.6	3.9	2.1	6.5 #	1.2	
C67 Bladder	129	72.9	1.8	1.5	2.1 #	6.8	7.0
C68 Urinary org.	3	0.9	3.3	0.7	9.6	0.3	66.7
C70-C72 CNS cancer	37	19.7	1.9	1.3	2.6 #	2.1	29.7
C73 Thyroid	16	9.0	1.8	1.0	2.9 #	0.8	12.5
C76-C79 CUP	38	27.1	1.4	1.0	1.9	1.3	2.6
C81 Hodgkin lymphoma	7	2.9	2.4	1.0	5.0	0.5	14.3
C82-C85 NHL	118	62.7	1.9	1.6	2.3 #	6.6	6.8
C90 Mult. myeloma	30	20.3	1.5	1.0	2.1	1.2	23.3
C91-C96 Leukaemia	47	26.0	1.8	1.3	2.4 #	2.5	40.4
Other primaries	14	13.0	1.1	0.6	1.8	0.1	7.1
Not observed	0	2.1	0.0	0.0	1.8	-0.2	

Patients 27962
 Median age at second malignancy (years) 73.1
 Person-years 83114
 Mean observation time (years) 3.0
 Median observation time (years) 1.6

The occurrence of second malignancy is statistically significant.

Observed second primaries with count 1 to 2 are pooled in category "Other primaries".

Table 6b

Standardized incidence ratio (SIR, with 95% confidence limits),
excess absolute risk (EAR) and DCO rate of second primaries
for period 1998-2013

FEMALES

Diagnosis	Observed n	Expected n	SIR	LCL 95%	UCL 95%	EAR	DCO %
C03-C06 Oral cavity	8	5.1	1.6	0.7	3.1	0.4	
C09-C10 Oropharynx	14	3.1	4.5	2.5	7.6 #	1.6	
C12-C13 Hypopharynx	4	0.8	4.8	1.3	12.3 #	0.5	25.0
C15 Oesophagus	9	5.0	1.8	0.8	3.4	0.6	22.2
C16 Stomach	76	39.0	1.9	1.5	2.4 #	5.3	26.3
C17 Small intestine	31	4.0	7.8	5.3	11.0 #	3.8	3.2
C18 Colon	290	104.1	2.8	2.5	3.1 #	26.5	7.2
C19-C20 Rectum	103	42.7	2.4	2.0	2.9 #	8.6	7.8
C21 Anus/canal	9	4.7	1.9	0.9	3.6	0.6	
C22 Liver	30	11.3	2.7	1.8	3.8 #	2.7	43.3
C23-C24 Bile	30	15.3	2.0	1.3	2.8 #	2.1	23.3
C25 Pancreas	90	44.1	2.0	1.6	2.5 #	6.5	23.3
C32 Larynx	6	1.5	4.0	1.5	8.6 #	0.6	
C33-C34 Lung	172	61.2	2.8	2.4	3.3 #	15.8	14.5
C38,C45 Mesothelioma	3	1.7	1.8	0.4	5.1	0.2	
C43 Malign. melanoma	54	29.5	1.8	1.4	2.4 #	3.5	
C46,C49 Soft tissue	11	5.2	2.1	1.1	3.8 #	0.8	
C48 Peritoneal	10	3.0	3.4	1.6	6.2 #	1.0	30.0
C50 Breast	426	254.5	1.7	1.5	1.8 #	24.4	7.7
C51 Vulva	21	9.8	2.1	1.3	3.3 #	1.6	4.8
C52 Vagina	5	1.9	2.6	0.9	6.2	0.4	20.0
C53 Cervix uteri	26	11.0	2.4	1.5	3.5 #	2.1	26.9
C54 Corpus uteri	94	48.6	1.9	1.6	2.4 #	6.5	5.3
C55,C57 Fem. genitals un	5	3.0	1.7	0.5	3.9	0.3	40.0
C56 Ovary	110	37.7	2.9	2.4	3.5 #	10.3	29.1
C64 Kidney	72	23.4	3.1	2.4	3.9 #	6.9	15.3
C65 Renal pelvis	7	2.9	2.4	1.0	4.9	0.6	
C66 Ureter	3	1.5	2.1	0.4	6.0	0.2	
C67 Bladder	39	20.0	1.9	1.4	2.7 #	2.7	17.9
C70-C72 CNS cancer	18	12.4	1.5	0.9	2.3	0.8	50.0
C73 Thyroid	20	12.9	1.6	0.9	2.4	1.0	10.0
C74-C80 Cancer others	4	5.2	0.8	0.2	2.0	-0.2	75.0
C76-C79 CUP	19	18.7	1.0	0.6	1.6	0.0	5.3
C82-C85 NHL	74	36.8	2.0	1.6	2.5 #	5.3	16.2
C90 Mult. myeloma	20	12.0	1.7	1.0	2.6 #	1.1	30.0
C91-C96 Leukaemia	38	15.6	2.4	1.7	3.3 #	3.2	42.1
Other primaries	16	9.5	1.7	1.0	2.7	0.9	12.5
Not observed	0	2.2	0.0	0.0	1.7	-0.3	

Patients 22925
 Median age at second malignancy (years) 75.6
 Person-years 70249
 Mean observation time (years) 3.1
 Median observation time (years) 1.6

The occurrence of second malignancy is statistically significant.

Observed second primaries with count 1 to 2 are pooled in category "Other primaries".




Figure 7. Age distribution and age-specific incidence




Figure 7a. Age-specific incidence in MCR registry areas compared to SEER (Surveillance, Epidemiology, and End Results, USA).

Reference:

Surveillance, Epidemiology, and End Results (SEER) Program SEER*Stat Database: Incidence - SEER 18 Regs Research Data, released April 2014, based on the November 2013 submission. <http://www.seer.cancer.gov>.





Figure 8. Cumulative follow-up years depending on time since diagnosis

The increase of the lost to follow-up rate can be interpreted as a consequence of a declining number of survivors over time.

Average incidence (world standard population) 2007 - 2013: Males



Average incidence (world standard population) 2007 - 2013: Females





Figure 9a. Map of cancer incidence (world standard population, incl. DCO cases) by county averaged for period 2007 to 2013. According to their individual incidence rates, the counties are displayed in different red and blue color temperatures where the fine white color indicates the population mean (males 72.6/100,000 WS N=22,827, females 42.1/100,000 WS N=17,600).

The results should be interpreted with caution! E.g., in county Ebersberg with a population of 64,928 female residents (averaged) in the period from 2007 to 2013 a total of 392 women were identified with newly diagnosed GI cancer. Therefore, the mean incidence rate for this cancer type in this area can be calculated at 37.5/100,000 (world standard population). Though, the value of this parameter may vary with an underlying probability of 99% between 32.2 and 43.6/100,000.

Standardized incidence ratio (SIR) 2007 - 2013: Males



Standardized incidence ratio (SIR) 2007 - 2013: Females




Figure 9b. Map of standardized incidence ratio (SIR, incl. DCO cases) by county averaged for period 2007 to 2013. According to their individual SIR values, the counties are displayed in different red and blue color temperatures where the fine white color indicates the population overall of 1.0 (males N=22,827, females N=17,600).

The results should be interpreted with caution! E.g., in county Ebersberg with a population of 64,642 female residents (averaged) in the period from 2007 to 2013 a total of 392 women were identified with newly diagnosed GI cancer. Therefore, the mean standardized incidence ratio (SIR) for this cancer type in this area can be calculated at 0.85. Though, the value of this parameter may vary with an underlying probability of 99% between 0.75 and 0.97.

MORTALITY

Table 10a

Patient cohorts of incident cancers by year of diagnosis, follow-up status, proportion of DCO, deaths among the annual cohorts, and proportion of available death certificates (with respect to registry area expansion from 2.51 to 3.96 m as of 2002, and from 3.96 to 4.64 m as of 2007, respectively)

Year of diagnosis	Incident cases n	Prop. actively followed %	Prop. DCO %	Deaths n	Prop. deaths %	Prop. deaths with death certific. %
1998	3204	98.6	11.7	2580	80.5	93.6
1999	3257	98.2	12.5	2611	80.2	94.5
2000	3045	98.7	13.7	2415	79.3	96.1
2001	3336	97.9	14.0	2534	76.0	96.3
2002	5717	98.6	19.3	4496	78.6	97.6
2003	5495	98.5	16.0	4085	74.3	98.0
2004	5545	97.9	14.2	4069	73.4	97.7
2005	5465	97.6	13.4	4009	73.4	98.1
2006	5630	96.4	10.7	3890	69.1	98.4
2007	6334	89.3	11.3	4332	68.4	98.3
2008	6335	79.4	10.9	4163	65.7	98.4
2009	6290	78.0	10.4	3947	62.8	98.3
2010	6021	76.8	10.5	3632	60.3	97.9
2011	5961	76.0	10.1	3351	56.2	97.3
2012	5904	76.9	10.3	2889	48.9	96.4
2013	4405	98.5	13.1	1594	36.2	92.1
1998-2013	81944	89.7	12.5	54597	66.6	97.2

Table 10b

Annual cohorts of incident cancers and deaths, proportion of death certificates and cases deceased the same year of cancer diagnosis
(incl. DCO)
(with respect to registry area expansion from 2.51 to 3.96 m as of 2002,
and from 3.96 to 4.64 m as of 2007, respectively)

Year of diagnosis/ death	Incident cases n	Deaths n	Prop. deaths with death certific. %	Deaths in same year n	Prop. deaths in same year %
1998	3204	2177	92.5	938	29.3
1999	3257	2262	92.1	979	30.1
2000	3045	2204	95.1	881	28.9
2001	3336	2353	95.6	969	29.0
2002	5717	3372	98.2	1968	34.4
2003	5495	3455	97.8	1678	30.5
2004	5545	3516	98.1	1613	29.1
2005	5465	3716	97.0	1607	29.4
2006	5630	3869	97.7	1609	28.6
2007	6334	4094	98.0	1760	27.8
2008	6335	4253	98.7	1832	28.9
2009	6290	4317	98.7	1715	27.3
2010	6021	4435	98.8	1676	27.8
2011	5961	4489	98.4	1706	28.6
2012	5904	4532	98.7	1733	29.4
2013	4405	4013	98.3	1263	28.7
1998-2013	81944	57057	97.5	23927	29.2

Table 10c

Annual cohorts of deaths, proportion of cancer-related and non-cancer-related deaths, and cancer recorded on death certificates
(incl. DCO)

(with respect to registry area expansion from 2.51 to 3.96 m as of 2002,
and from 3.96 to 4.64 m as of 2007, respectively)

Year of death	Deaths n	Prop. cancer- related %	Prop. non-cancer- related %	Prop. cancer recorded on death certificate %
1998	2177	76.3	23.7	91.3
1999	2262	80.0	20.0	91.6
2000	2204	81.7	18.3	91.2
2001	2353	78.4	21.6	91.0
2002	3372	82.9	17.1	91.8
2003	3455	81.9	18.1	91.2
2004	3516	83.4	16.6	91.0
2005	3716	81.3	18.7	89.1
2006	3869	81.4	18.6	89.6
2007	4094	80.7	19.3	89.2
2008	4253	81.3	18.7	88.5
2009	4317	79.8	20.2	87.5
2010	4435	78.1	21.9	86.6
2011	4489	77.9	22.1	86.7
2012	4532	77.4	22.6	86.1
2013	4013	74.4	25.6	82.5
1998-2013	57057	79.7	20.3	88.6

Table 11a

Medians of age at death according to the grouping in Table 10

MALES

Year of death	Deaths n	Age at death (all causes) Years	Age at death (cancer-related) Years	Age at death (non-cancer-related) Years	Age at death (according to death certificate) Years
1998	1103	72.5	70.8	78.4	72.2
1999	1184	72.3	70.6	77.9	71.8
2000	1157	72.8	70.9	80.7	71.9
2001	1222	71.9	70.1	79.5	71.1
2002	1793	72.3	70.7	79.9	71.7
2003	1886	72.6	71.2	78.9	72.2
2004	1879	73.6	71.8	80.5	72.7
2005	2029	73.0	71.2	80.3	71.6
2006	2151	73.7	71.8	80.2	72.6
2007	2279	73.2	71.9	80.2	72.5
2008	2375	74.2	72.7	80.5	73.3
2009	2428	73.6	71.8	80.0	72.5
2010	2468	74.2	72.8	81.2	73.5
2011	2571	74.2	72.5	81.8	73.3
2012	2553	74.9	73.2	81.0	73.8
2013	2247	75.8	73.6	82.7	74.3
1998-2013	31325	73.7	72.0	80.4	72.8

Deaths of patients are considered to be cancer-related, in case that fact was recorded on the death certificate, or patients had suffered from metastasis or recurrence.

Table 11b

Medians of age at death according to the grouping in Table 10
FEMALES

Year of death	Deaths n	Age at death (all causes) Years	Age at death (cancer-related) Years	Age at death (non-cancer-related) Years	Age at death (according to death certificate) Years
1998	1074	78.2	76.2	84.3	78.3
1999	1078	79.5	78.0	84.9	79.2
2000	1047	79.2	78.0	85.4	78.8
2001	1131	79.3	77.2	86.7	78.7
2002	1579	79.8	78.6	85.7	79.3
2003	1569	79.6	77.8	85.7	78.7
2004	1637	79.8	78.2	84.8	78.8
2005	1687	79.8	78.1	84.9	78.8
2006	1718	80.2	78.4	85.8	79.2
2007	1815	80.1	77.8	86.4	78.9
2008	1878	80.3	78.1	86.4	79.1
2009	1889	80.7	78.2	86.9	79.0
2010	1967	80.9	78.2	86.7	79.4
2011	1918	80.8	77.8	87.5	78.8
2012	1979	80.5	77.2	87.7	78.1
2013	1766	81.0	77.2	87.9	78.7
1998-2013	25732	80.1	77.9	86.4	78.9

By 2010, life expectancy for a newborn male in Germany is 77.5 years compared with 82.6 years for his female counterpart.

Deaths of patients are considered to be cancer-related, in case that fact was recorded on the death certificate, or patients had suffered from metastasis or recurrence.

Table 12a

Mortality measures (cancer-related death) and mortality-incidence-index
by year of death

MALES

Year of death	Deaths n	Mort. raw	MI-Index raw	Mort. WS	MI-Index WS	Mort. ES	MI-Index ES	Mort. BRD-S	MI-Index BRD-S
1998	846	76.4	0.51	44.8	0.50	69.7	0.52	94.2	0.53
1999	956	85.4	0.56	49.6	0.55	77.1	0.57	104.6	0.59
2000	949	83.3	0.59	47.6	0.57	74.3	0.59	99.9	0.61
2001	982	84.7	0.56	48.5	0.55	75.2	0.56	99.0	0.58
2002	1486	79.8	0.49	43.9	0.48	67.5	0.49	89.5	0.50
2003	1567	83.6	0.54	44.7	0.52	69.2	0.53	93.0	0.55
2004	1582	84.1	0.54	43.4	0.51	67.8	0.53	92.6	0.56
2005	1682	88.8	0.58	45.2	0.56	69.6	0.57	94.2	0.59
2006	1754	91.6	0.58	45.6	0.55	71.1	0.57	96.3	0.59
2007	1861	84.0	0.53	41.2	0.50	63.8	0.52	86.6	0.54
2008	1972	88.6	0.57	42.6	0.54	66.4	0.56	90.5	0.59
2009	1962	87.9	0.56	42.4	0.54	65.0	0.55	86.0	0.56
2010	1953	86.7	0.58	40.2	0.55	62.1	0.56	84.0	0.59
2011	2031	88.9	0.61	41.4	0.59	63.7	0.60	84.5	0.62
2012	1998	87.5	0.62	39.9	0.57	61.9	0.60	83.6	0.63
2013	1711	74.9	0.70	34.1	0.67	53.2	0.69	71.7	0.71
1998-2013	25292	85.1	0.57	42.5	0.54	65.7	0.56	88.4	0.58

Table 12b

Mortality measures (cancer-related death) and mortality-incidence-index
by year of death

FEMALES

Year of death	Deaths n	Mort. raw	MI-Index raw	Mort. WS	MI-Index WS	Mort. ES	MI-Index ES	Mort. BRD-S	MI-Index BRD-S
1998	817	69.5	0.53	26.9	0.50	42.0	0.51	57.5	0.53
1999	855	72.1	0.56	26.3	0.50	41.7	0.52	57.7	0.54
2000	853	71.0	0.61	25.9	0.55	41.1	0.57	56.0	0.59
2001	863	70.9	0.56	26.7	0.50	42.2	0.52	57.2	0.55
2002	1311	67.0	0.50	23.8	0.45	37.5	0.46	51.4	0.48
2003	1263	64.1	0.50	23.5	0.46	36.9	0.48	50.1	0.49
2004	1350	68.3	0.54	23.9	0.46	37.8	0.48	52.0	0.51
2005	1338	67.2	0.54	24.0	0.49	37.5	0.51	50.8	0.53
2006	1399	69.6	0.56	23.7	0.48	37.6	0.51	52.1	0.54
2007	1450	62.8	0.53	22.5	0.49	34.9	0.50	47.3	0.52
2008	1487	64.1	0.54	22.2	0.48	34.8	0.50	47.2	0.52
2009	1482	63.7	0.56	21.8	0.49	34.1	0.51	46.5	0.53
2010	1511	64.6	0.59	21.7	0.52	34.0	0.54	46.2	0.56
2011	1470	62.3	0.58	21.0	0.50	32.7	0.52	44.3	0.55
2012	1512	64.1	0.60	22.0	0.51	34.3	0.54	46.2	0.56
2013	1277	54.1	0.68	18.5	0.59	28.8	0.62	39.0	0.64
1998-2013	20238	65.2	0.56	22.8	0.49	35.8	0.52	48.8	0.54

Table 13

Age distribution of age at death (cancer-related) for period 1998-2013
(incl. multiple primaries)

Age at death Years	Cases			Males			Females		
	n	%	Cum.%	n	%	Cum.%	n	%	Cum.%
0-4	2	0.0	0.0	1	0.0	0.0	1	0.0	0.0
5-9	1	0.0	0.0	1	0.0	0.0			0.0
10-14	2	0.0	0.0	1	0.0	0.0	1	0.0	0.0
15-19	3	0.0	0.0	2	0.0	0.0	1	0.0	0.0
20-24	10	0.0	0.0	6	0.0	0.0	4	0.0	0.0
25-29	36	0.1	0.1	13	0.0	0.1	23	0.1	0.1
30-34	74	0.2	0.3	36	0.1	0.2	38	0.2	0.3
35-39	173	0.4	0.6	97	0.4	0.6	76	0.4	0.7
40-44	419	0.9	1.5	261	1.0	1.6	158	0.8	1.4
45-49	906	1.9	3.4	548	2.1	3.6	358	1.7	3.1
50-54	1692	3.6	7.0	1081	4.1	7.7	611	2.9	6.1
55-59	2998	6.3	13.3	2016	7.6	15.3	982	4.7	10.7
60-64	4653	9.8	23.1	3138	11.8	27.2	1515	7.2	18.0
65-69	6122	12.9	36.0	4074	15.4	42.5	2048	9.8	27.7
70-74	7374	15.5	51.5	4553	17.2	59.7	2821	13.4	41.2
75-79	7662	16.1	67.7	4338	16.4	76.1	3324	15.8	57.0
80-84	7280	15.3	83.0	3477	13.1	89.2	3803	18.1	75.1
85+	8077	17.0	100.0	2857	10.8	100.0	5220	24.9	100.0
All ages	47484	100.0		26500	100.0		20984	100.0	

Included in the statistics are 27.9% multiple primaries in males and 23.4% in females.

Table 14

Age-specific mortality (cancer-related) and proportion of all cancers
for period 1998-2013
(incl. multiple primaries)

Age at death Years	Males n	Females n	Males Age- spec. mortal.	MI-index	Females Age- spec. mortal.	MI-index	Males Prop.all cancers %	Females Prop.all cancers %
0- 4	1	1	0.1	0.13	0.1	0.10	3.0	3.8
5- 9	1		0.1	0.25	0.0		2.6	
10-14	1	1	0.1	0.25	0.1	0.20	2.9	3.2
15-19	2	1	0.1	0.20	0.1	0.04	4.4	2.7
20-24	6	4	0.3	0.38	0.2	0.10	6.7	7.8
25-29	13	23	0.6	0.22	1.1	0.32	12.0	20.0
30-34	36	38	1.6	0.27	1.7	0.27	19.4	16.7
35-39	97	76	3.9	0.32	3.2	0.32	24.3	14.7
40-44	261	158	10.0	0.40	6.3	0.31	30.5	13.9
45-49	548	358	23.2	0.41	15.5	0.37	30.3	17.8
50-54	1081	611	53.5	0.44	29.7	0.39	32.8	19.7
55-59	2016	982	109.9	0.49	51.1	0.43	34.1	20.7
60-64	3138	1515	177.0	0.51	80.8	0.45	35.3	23.2
65-69	4074	2048	258.1	0.54	118.7	0.50	34.1	24.6
70-74	4553	2821	355.4	0.58	185.8	0.55	33.5	28.5
75-79	4338	3324	524.9	0.66	279.9	0.60	32.9	31.0
80-84	3477	3803	694.9	0.74	407.7	0.66	32.0	33.9
85+	2857	5220	837.8	0.83	584.0	0.76	32.2	38.2
All ages	26500	20984					33.1	29.0
Mortality								
Raw			89.1	0.58	67.6	0.57		
WS			44.3	0.56	23.5	0.50		
ES			68.8	0.58	37.0	0.53		
BRD-S			92.8	0.60	50.5	0.55		
PYLL-70								
per 100,000			384.5		215.2			
ES			337.0		183.1			
AYLL-70			9.1		9.8			

The rates underestimate the prognosis if other synchronous cancers are prognostic unfavorable.

Table 15a

Multiple primaries in deaths in period 1998-2013
MALES

Diagnosis	Total n	Total %↓	Pre n	Pre ←%	Syn- chron ±30d n	Syn- chron ±30d ←%	Post n	Post ←%
C03-C06 Oral cavity	146	1.9	109	74.7	12	8.2	25	17.1
C09-C10 Oropharynx	162	2.2	105	64.8	19	11.7	38	23.5
C12-C13 Hypopharynx	90	1.2	58	64.4	10	11.1	22	24.4
C16 Stomach	189	2.5			41	21.7	148	78.3
C18 Colon	477	6.3			184	38.6	293	61.4
C19-C20 Rectum	248	3.3			134	54.0	114	46.0
C22 Liver	165	2.2			37	22.4	128	77.6
C25 Pancreas	220	2.9			50	22.7	170	77.3
C32 Larynx	172	2.3	129	75.0	13	7.6	30	17.4
C33-C34 Lung	834	11.1	193	23.1	163	19.5	478	57.3
C43 Malign. melanoma	292	3.9	206	70.5	5	1.7	81	27.7
C44 Skin others	420	5.6	246	58.6	34	8.1	140	33.3
C61 Prostate	1800	23.9	1199	66.6	133	7.4	468	26.0
C64 Kidney	322	4.3	174	54.0	61	18.9	87	27.0
C67 Bladder	640	8.5	374	58.4	50	7.8	216	33.8
C70-C72 CNS cancer	120	1.6	47	39.2	10	8.3	63	52.5
C76-C79 CUP	98	1.3	40	40.8	21	21.4	37	37.8
C82-C85 NHL	285	3.8	146	51.2	45	15.8	94	33.0
C90 Mult. myeloma	95	1.3	38	40.0	15	15.8	42	44.2
C91-C96 Leukaemia	156	2.1	47	30.1	17	10.9	92	59.0
Other primaries	592	7.9	213	36.0	62	10.5	317	53.5
All mult. primaries	7523	100.0	3324	44.2	1116	14.8	3083	41.0

Multiple primaries with number of cases 1 to 69 are pooled in category "Other primaries".

ICD-10 C44 (Other malignant neoplasms of skin) is not systematically recorded by MCR and therefore not considered for evaluation as a particular primary but at least as a multiple malignancy.

Table 15b

Multiple primaries in deaths in period 1998-2013
FEMALES

Diagnosis		Total n	Total %↓	Pre n	Pre ←%	Syn- chron ±30d n	Syn- chron ±30d ←%	Post n	Post ←%
C16	Stomach	125	2.4			20	16.0	105	84.0
C18	Colon	317	6.0			103	32.5	214	67.5
C19-C20	Rectum	144	2.7			74	51.4	70	48.6
C25	Pancreas	177	3.3			36	20.3	141	79.7
C33-C34	Lung	317	6.0	67	21.1	41	12.9	209	65.9
C43	Malign. melanoma	162	3.1	127	78.4	7	4.3	28	17.3
C44	Skin others	174	3.3	109	62.6	14	8.0	51	29.3
C50	Breast	1573	29.7	1169	74.3	113	7.2	291	18.5
C51	Vulva	51	1.0	31	60.8	2	3.9	18	35.3
C53	Cervix uteri	174	3.3	133	76.4	13	7.5	28	16.1
C54	Corpus uteri	343	6.5	257	74.9	19	5.5	67	19.5
C56	Ovary	338	6.4	138	40.8	73	21.6	127	37.6
C64	Kidney	146	2.8	84	57.5	30	20.5	32	21.9
C67	Bladder	195	3.7	121	62.1	10	5.1	64	32.8
C70-C72	CNS cancer	100	1.9	48	48.0	15	15.0	37	37.0
C73	Thyroid	64	1.2	45	70.3	4	6.3	15	23.4
C76-C79	CUP	64	1.2	23	35.9	18	28.1	23	35.9
C82-C85	NHL	170	3.2	91	53.5	24	14.1	55	32.4
C90	Mult. myeloma	67	1.3	23	34.3	9	13.4	35	52.2
C91-C96	Leukaemia	99	1.9	26	26.3	12	12.1	61	61.6
Other primaries		489	9.2	195	39.9	86	17.6	208	42.5
All mult. primaries		5289	100.0	2687	50.8	723	13.7	1879	35.5

Multiple primaries with number of cases 1 to 48 are pooled in category "Other primaries".

ICD-10 C44 (Other malignant neoplasms of skin) is not systematically recorded by MCR and therefore not considered for evaluation as a particular primary but at least as a multiple malignancy.

Table 16

Age-specific mortality (cancer-related) and proportion of all cancers
for period 1998-2013
(Singular primaries only *)

Age at death Years	Males n	Females n	Males Age- spec. mortal.	MI-index	Females Age- spec. mortal.	MI-index	Males Prop.all cancers %	Females Prop.all cancers %
0- 4	1	1	0.1	0.13	0.1	0.10	3.6	4.2
5- 9	1		0.1	0.25	0.0		2.8	
10-14	1	1	0.1	0.25	0.1	0.20	2.9	3.4
15-19	2	1	0.1	0.20	0.1	0.04	4.8	3.0
20-24	5	4	0.3	0.33	0.2	0.10	6.0	8.5
25-29	13	22	0.6	0.24	1.1	0.32	13.1	20.2
30-34	35	34	1.5	0.27	1.5	0.26	19.3	16.9
35-39	91	68	3.7	0.33	2.9	0.30	24.3	14.6
40-44	246	145	9.4	0.40	5.8	0.31	31.2	14.6
45-49	508	318	21.5	0.41	13.8	0.36	31.0	18.4
50-54	967	528	47.9	0.44	25.7	0.38	33.6	20.3
55-59	1759	853	95.9	0.48	44.4	0.44	34.5	21.3
60-64	2683	1264	151.4	0.51	67.4	0.44	35.9	23.7
65-69	3380	1710	214.1	0.55	99.1	0.51	34.9	25.5
70-74	3657	2295	285.5	0.60	151.2	0.56	34.2	29.3
75-79	3302	2656	399.5	0.67	223.6	0.59	33.1	31.0
80-84	2596	3051	518.8	0.76	327.1	0.65	32.1	34.4
85+	2144	4267	628.7	0.84	477.4	0.75	31.9	38.7
All ages	21391	17218					33.5	29.4
Mortality								
Raw			71.9	0.58	55.4	0.57		
WS			36.4	0.56	19.6	0.50		
ES			55.9	0.57	30.6	0.52		
BRD-S			74.2	0.60	41.5	0.54		
PYLL-70								
per 100,000			339.9		186.9			
ES			298.2		159.4			
AYLL-70			9.4		10.0			

* See corresponding tables with multiple primaries.

Table 17

Age-specific mortality (cancer-related) and proportion of all cancers
for period 1998-2013
(Single primaries only *)

Age at death Years	Males n	Females n	Males Age- spec. mortal.	MI-index	Females Age- spec. mortal.	MI-index	Males Prop.all cancers %	Females Prop.all cancers %
0- 4	1	1	0.1	0.13	0.1	0.10	3.7	4.2
5- 9	1		0.1	0.25	0.0		2.9	
10-14	1	1	0.1	0.25	0.1	0.20	2.9	3.7
15-19	2	1	0.1	0.20	0.1	0.04	4.8	3.6
20-24	5	4	0.3	0.33	0.2	0.10	6.3	9.1
25-29	12	22	0.6	0.24	1.1	0.32	13.0	21.4
30-34	34	33	1.5	0.27	1.5	0.26	19.4	18.1
35-39	89	64	3.6	0.33	2.7	0.29	24.9	15.0
40-44	241	140	9.2	0.40	5.6	0.31	32.3	15.3
45-49	493	306	20.9	0.42	13.2	0.36	32.1	19.7
50-54	928	515	46.0	0.45	25.0	0.39	35.6	22.0
55-59	1673	801	91.2	0.49	41.7	0.44	36.2	22.5
60-64	2495	1189	140.8	0.51	63.4	0.45	37.9	25.6
65-69	3110	1581	197.0	0.56	91.6	0.50	37.2	27.8
70-74	3258	2105	254.3	0.58	138.6	0.55	36.5	32.1
75-79	2889	2438	349.5	0.64	205.3	0.58	36.1	33.9
80-84	2180	2777	435.7	0.69	297.7	0.62	34.1	37.4
85+	1798	3886	527.3	0.74	434.8	0.71	33.4	41.1
All ages	19210	15864					35.6	31.6
Mortality								
Raw			64.6	0.57	51.1	0.55		
WS			33.1	0.55	18.2	0.49		
ES			50.4	0.56	28.4	0.51		
BRD-S			66.3	0.58	38.3	0.53		
PYLL-70								
per 100,000			323.2		178.1			
ES			283.8		152.1			
AYLL-70			9.5		10.1			

* See corresponding tables with multiple primaries.





Figure 18. Distribution of age at death (bars) and age-specific mortality (all patients: solid line, patients with single primaries: dotted line). The age-specific incidence is additionally plotted for comparison (dashed line).

The difference between age at diagnosis (Table 3) and age at GI cancer-related death (see Table 10) should be considered.

Average mortality (world standard population) 2007 - 2013: Males



Average mortality (world standard population) 2007 - 2013: Females





Figure 19a. Map of cancer mortality (world standard population) by county averaged for period 2007 to 2013. According to their individual mortality rates, the counties are displayed in different red and blue color temperatures where the fine white color indicates the population mean (males 40.2/100,000 WS N=13,405, females 21.3/100,000 WS N=10,112).

The results should be interpreted with caution! E.g., in county Ebersberg with a population of 64,928 female residents (averaged) in the period from 2007 to 2013 a total of 247 women died from GI cancer. Therefore, the mean mortality rate for this cancer type in this area can be calculated at 20.2/100,000 (world standard population). Though, the value of this parameter may vary with an underlying probability of 99% between 16.6 and 24.6/100,000.

Standardized mortality ratio (SMR) 2007 - 2013: Males



Standardized mortality ratio (SMR) 2007 - 2013: Females




Figure 19b. Map of standardized mortality ratio (SMR, incl. DCO cases) by county averaged for period 2007 to 2013. According to their individual SMR values, the counties are displayed in different red and blue color temperatures where the fine white color indicates the population overall of 1.0 (males N=13,405, females N=10,112).

The results should be interpreted with caution! E.g., in county Ebersberg with a population of 64,642 female residents (averaged) in the period from 2007 to 2013 a total of 247 women died from GI cancer. Therefore, the mean standardized mortality ratio (SMR) for this cancer type in this area can be calculated at 0.95. Though, the value of this parameter may vary with an underlying probability of 99% between 0.80 and 1.12, and is therefore not statistically striking.

Statistical Notes

In all tables and figures the respective reference values should be carefully considered. The incidence rates include diagnoses (with multiple primary), and death certificate only (DCO) cases. For mortality statistics patients, diagnoses and progressive course of disease are presented. In the calculations, all courses of disease are considered whereby progressions occurred and/or death certificate identified progressive cancers were ascertained. Additionally there are three groups of disease course to consider:

1. All multiple primaries included

The mortality statistic describes the tumor-specific death, independent of any malignancy. The patient perspective, induced secondary malignancies, and the problem of multiple malignancies from the same primary tumor all have reasons for their inclusion.

2. First singular primary (no information about other prior or synchronous malignancy)

The mortality statistic describes the cancer-related death for patients who have no therapeutic restrictions due to a previous or synchronous cancer. These statistics are comparable to studies that have exclusion criteria based on a second malignancy.

3. Single primary (no information about other prior, syn- or metachronous malignancy)

The mortality statistic describes the tumor-specific death that occurs without any impact through secondary primaries, earlier, synchronous, later or induced. Precisely the difference between disease group 1 and 2 highlight the magnitude of the problem of secondary malignancies.

For this reason differences appear concerning official mono-causal mortality statistics. To judge the maximum deviation, 2 further tables are presented. In the first table the distribution of secondary malignancies before, at or after the described cancer are shown, that could be an alternative cause of death. In the second table, the age-specific mortality rates for all courses of disease, without designation of secondary malignancies are shown.

A previously minimally acknowledged statistic is the **age at death**, which allows for a good assessment of the quality of classification of the apparent tumor-specific death. For assumed tumor-independent deaths, the age of death should be estimated from the age of diagnosis and the normal life expectancy, whereas tumor-dependent deaths can be estimated from the age of diagnosis plus the average tumor-specific life expectancy. The comparison of different tumors demonstrates this association, if the causes of cancer and the competing cause of death are independent of each other (e.g. breast and colon versus head/neck and lung).

The index from mortality and incidence (Mortality-Incidence ratio, **MI-index**) is a statistic that allows for the evaluation of the quality of data. For diseases with poor prognoses, comparable values are obtained from all age groups, because to a large extent, the numerator and denominator contain the same cases. For tumors with a good prognosis, increasing and decreasing incidence and age-specific differences in prognosis can more strongly alter the MI- index. Additionally, attention should be paid to the confidence intervals where fewer cases are reported.

The complexity of problems identified here emphasizes the importance of relative survival data for the appropriate analysis of long term results.

As a measurement of the burden of disease, the number of potential life years loss due to premature deaths in a cohort can be calculated (**PYLL**, potential years of life lost, standardized per 100,000 persons or per European standard) as well as the average loss of life years per individual (**AYLL**, average years of life lost). Depending upon the analytic aim (health economy, prevention, health care research) different methods exist for the generation of these measurements. In the results presented here, the age for a premature death is considered to be before 70 years, according to the guidelines of the OECD and the WHO (as seen in the abbreviation PYLL-70 or AYLL-70).

Shortcuts

FRG	Federal Republic of Germany
GEKID	Association of Population-based Cancer Registries in Germany (Gesellschaft der epidemiologischen Krebsregister in Deutschland e.V.)
MCR	Munich Cancer Registry (Tumorregister München)
SEER	Surveillance, Epidemiology, and End Results (USA)
AYLL-70	Average years of life lost prior to age 70 given a person dies before that age
BRD-S	German standard population
DCO	Death certificate only
EAR	Excess absolute risk = excess cancer cases (O - E) per 10,000 person-years
ES	European standard population (old)
LCL	Lower confidence limit
MI-index	Ratio between mortality and incidence
PYLL-70	Potential years of life lost prior to age 70 given a person dies before that age
SIR	Standardized incidence ratio
SMR	Standardized mortality ratio
UCL	Upper confidence limit
WS	World standard population

Recommended Citation

Munich Cancer Registry. Baseline statistics C15-C26: GI cancer [Internet]. 2015 [updated 2015 May 19; cited 2015 Jul 1]. Available from: http://www.tumorregister-muenchen.de/en/facts/base/base_C1526E.pdf

Copyright

The content of the public web site provided by the Munich Cancer Registry is available worldwide and free of charge. All documents are free to download, utilize, copy, print-out and distribute, providing that the MCR is referenced.

Disclaimer

The Munich Cancer Registry reserves the right to not be responsible for the topicality, correctness, completeness or quality of the information provided. Liability claims regarding damage caused by the use of any information provided, including any kind of information which is incomplete or incorrect, will therefore be rejected.

Index of figures and tables

Fig./Tbl.	Page
1 Pts cohorts, DCO, mult. prim., follow-up / yr	4
1a Gender distribution by year of diagnosis	5
2 Incidence by year of diagnosis	6
3 Age distribution parameters by year of diagnosis	7
4 Age distribution by 5-year age group and gender	9
5 Age-specific incidence and DCO rate	10
6 Standardized incidence ratio of second primaries	11
7 Age distribution and age-specific incidence (chart)	13
7a Age-specific incidence internationally (chart)	14
8 Cumulative follow-up years (chart)	15
9a Map of cancer incidence (WS) by county (chart)	16
9b Standardized incidence ratio (SIR) by county (chart)	17
10a Pts incident cohorts and mortality / yr	18
10b Incidence and mortality by year of diagnosis	19
10c Cancer-related deaths, death certification available / yr	20
11 Medians of age at death / yr	21
12 Mortality by year of death	23
13 Distribution of age at death	24
14 Age-specific mortality	25
15 Multiple primaries in deaths	26
16 Age-specific mortality (first primaries)	28
17 Age-specific mortality (single primaries)	29
18 Age distribution and age-specific mortality (chart)	30
19a Map of cancer mortality (WS) by county (chart)	31
19b Standardized mortality ratio (SMR) by county (chart)	32